Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Byoung Chul Cho(Yonsei University), Igor Bondarenko(Dnipro State Medical University), Iveta Kudaba(Riga East University Hospital), Tony Mok(Chinese University of Hong Kong), Gilberto Lopes(University of Miami), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Vichien Srimuninnimit(Siriraj Hospital), К. К. Лактионов(Russian Cancer Research Center NN Blokhin), Rinee Mukherjee(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bogusława Karaszewska(State University of Applied Sciences in Konin), Li Zhang(Fourth Hospital of Changsha), Yi‐Long Wu(Guangdong Academy of Medical Sciences), H.Z. Turna(Istanbul University-Cerrahpaşa), Jianxin Lin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kaoru Kubota(Nippon Medical School Hospital), Fabricio Souza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christian Caglevic
Cited by 334
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs
|Cell stem cell|2008|4k